Related Experiment Video
Updated: Jun 9, 2025
03:42
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
1.4K
Lomitapide: navigating cardiovascular challenges with innovative therapies
Undral Munkhsaikhan1, Karima Ait-Aissa1, Amal M Sahyoun1
1College of Dental Medicine, Lincoln Memorial University, LMU tower, 1705 St. Mary Street, Knoxville, TN, 37917, USA.
Molecular Biology Reports
|October 21, 2024
Summary
Dyslipidemia increases cardiovascular disease risk. Lomitapide, a microsomal triglyceride transfer protein inhibitor, effectively lowers LDL-C in HoFH patients unresponsive to statins, reducing cardiovascular risks.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Genetics
Background:
- Dyslipidemia is a primary risk factor for cardiovascular diseases (CVDs).
- Homozygous Familial Hypercholesterolemia (HoFH) is a severe inherited condition characterized by extremely high LDL-C levels.
- Statins are the primary treatment for dyslipidemia, but HoFH patients often show limited response.
Purpose of the Study:
- To review the therapeutic benefits of lomitapide for managing dyslipidemia, particularly in HoFH.
- To highlight lomitapide's efficacy in lowering cholesterol levels and reducing CVD risk.
- To explore lomitapide as an alternative therapy for HoFH patients.
Main Methods:
- Systematic review and meta-analysis of interventional studies.
- Focus on research findings regarding lomitapide's effectiveness.
- Analysis of lomitapide's mechanism of action as a microsomal triglyceride transfer protein (MTP) inhibitor.
Main Results:
- Lomitapide significantly reduces LDL-C levels by over 50% in HoFH patients.
- Lomitapide lowers ApoB-containing proteins and VLDL, indirectly decreasing LDL-C.
- Studies indicate improved vascular function and reduced cardiovascular risk with lomitapide treatment.
Conclusions:
- Lomitapide is an effective therapeutic option for HoFH patients with inadequate response to other treatments.
- MTP inhibition with lomitapide offers a novel approach to managing severe dyslipidemia.
- Lowering LDL-C with lomitapide is crucial for preventing atherosclerosis and improving cardiovascular health in HoFH.
Related Concept Videos
01:26Coronary Artery Disease IV: Medical Management
3
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
3
01:29Cardiomyopathy V: Interprofessional Care
1
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
1
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
136
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
136
01:26Atherosclerosis III: Management
1
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
1
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
154
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
154
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
142
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
142